How do you approach using non-anthracycline based neoadjuvant treatment for triple negative breast cancer, especially in older patients with node negative disease?

Topics: Breast Cancer • Medical Oncology • Triple negative

For example: do you use docetaxel + cyclophosphamide (TC) x4 and what is the evidence for using such a regimen

Answer from: Medical Oncologist at Academic Institution

There is compelling data that including carboplatin in neoadjuvant therapy for TNBC significantly increases pCR rates, and may allow omission of an anthracycline without compromising long-term outcomes. Until very recently, my anthracycline-free neoadjuvant regimen of choice was every 3-weeks doceta...

Comments

Medical Oncologist at Medical College of Wisconsin
In a recent local study, we've found weekly Carbo/...

Medical Oncologist at Warren Alpert Medical School of Brown University
In my experience, clinically significant myelosupp...

Medical Oncologist at Cancer Health Treatment Centers, PC
I am reviewing Phase 2 comparison of neoadjuvant n...

Medical Oncologist at Warren Alpert Medical School of Brown University
I suspect that nab-paclitaxel may well be superior...

Related Questions